Request the Cancerguard™ test*
Screen for cancer types responsible for 80% of diagnoses, including aggressive and hard-to-find types. All with one simple blood draw.
Also available through your provider
Prefer to speak with your health care provider first? The Cancerguard test can be prescribed by your provider at any time upon request.
Common questions about ordering the Cancerguard test
The Cancerguard test is a multi‑cancer early detection blood test designed for adults aged 50–84 with no active cancer diagnosis in the past three years. It’s used in addition to—not instead of—routine cancer screenings. If you smoke or cancer runs in your family, you may be at higher risk and may benefit from additional screening. Talk to your doctor to see if Cancerguard is right for you.
- Your healthcare provider will order the Cancerguard test if they determine it's right for you
2 - You’ll complete a simple blood draw, either at your doctor's office, a nearby lab, or through a mobile lab that comes to your home.
2 - Results are usually ready in about 2 weeks. You can review them with your doctor.
2
- You’ll get a clear negative or positive result, which tells you whether signals of cancer are present, so you and your doctor can make an informed plan to move forward.
1 - Negative: No cancer signals detected. Continue with your regular screening plan, since it doesn't completely rule out the possibility of cancer.
1 - Positive: Cancer signals were found. This isn’t a diagnosis—it simply means that you need imaging and further tests.
1 You’ll also be able to take advantage of personalized support through our Care Navigation services, including help with follow-up steps and potential imaging reimbursement for eligible patients.
Footnotes and references
Important Information about the Cancerguard Test
Rx only. Talk to your healthcare provider to determine if this test is right for you.
The Cancerguard™ test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant. Results should be interpreted in the context of a patient’s medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard™ test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (18F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV- contrast) may be appropriate in the context of the patient’s medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.
The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.